SecBot SecBot
8-K ·Filed Jun 1, 2026

ORKA

Oruka Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001213900-26-063481
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a material pipeline expansion for ORKA-001 into IBD, a large and competitive market with established IL-23 blockbusters (Skyrizi, Stelara). The dosing restrictions create a clear timeline catalyst: watch for IND filings or Phase I starts in IBD after June 2028. The change-of-control acceleration clause also makes Oruka a more attractive M&A target.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$55.23
T+0 close · Jun 1, 2026 · via day close
Latest settled
+80.05%
T+60 · $99.44
Vs SPY
+78.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $55.23entry
  2. T+1 · 6mo ago +3.57%α +4.26% · $57.20
  3. T+5 · 5mo ago +21.18%α +24.15% · $66.93
  4. T+20 · 5mo ago +68.91%α +70.48% · $93.29
  5. T+60 · 3mo ago +80.05%α +78.93% · $99.44
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include inflammatory bowel disease (IBD), removing a key restriction on ORKA-001's addressable market. The amendment imposes dosing restrictions (no monotherapy IBD dosing until June 2030, no combination dosing until June 2028), but these accelerate to June 2028 upon a material transaction like a change of control. This significantly expands the commercial opportunity for ORKA-001, a $3.5B market cap biotech's lead asset.

Key Facts

  • Oruka expanded the field of use for its IL-23 license to include all therapeutic areas, including inflammatory bowel disease (IBD), which was previously excluded.
  • Monotherapy dosing of ORKA-001 for IBD is restricted until June 1, 2030; combination dosing until June 1, 2028.
  • Upon a material transaction (change of control or sale of Phase II-stage assets), the monotherapy restriction accelerates to June 1, 2028.
  • Paragon granted Oruka exclusivity in the IBD field until October 11, 2029, and Oruka granted Paragon a non-exclusive cross-license for retained antibodies outside IBD.
  • The amendment was signed May 29, 2026, and filed June 1, 2026.

Financial Impact

No financial terms disclosed; the amendment expands the addressable market for ORKA-001 to include IBD, a multi-billion-dollar therapeutic area.

pipeline valueaddressable market

Risk Factors

  • IBD market is highly competitive with approved IL-23 inhibitors (Skyrizi, Stelara, Tremfya), ORKA-001 must differentiate on efficacy, safety, or dosing.
  • Dosing restrictions delay IBD clinical development until at least 2028, limiting near-term value inflection.
  • No financial consideration disclosed, the amendment's value depends entirely on ORKA-001's clinical profile in IBD, which is unproven.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-063481
Document: ea029287601ex10-1.htm0001213900-26-063481
Document: 0001213900-26-063481-index-headers.html0001213900-26-063481
Document: 0001213900-26-063481-index.html0001213900-26-063481
Document: 0001213900-26-063481.txt0001213900-26-063481

Track record

40 reports on ORKA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +21.13% at T+60 after the Apr 27, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 8h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026